• 1
    Lacroix M,Toillon RA,Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006; 13: 293325.
  • 2
    Olivier M,Langerod A,Carrieri P,Bergh J,Klaar S,Eyfjord J,Theillet C,Rodriguez C,Lidereau R,Bieche I,Varley J,Bignon Y, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12: 115767.
  • 3
    Bull SB,Ozcelik H,Pinnaduwage D,Blackstein ME,Sutherland DA,Pritchard KI,Tzontcheva AT,Sidlofsky S,Hanna WM,Qizilbash AH,Tweeddale ME,Fine S, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 2004; 22: 8696.
  • 4
    Pharoah PD,Day NE,Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80: 196873.
  • 5
    Bergh J,Norberg T,Sjogren S,Lindgren A,Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 102934.
  • 6
    Sjogren S,Inganas M,Norberg T,Lindgren A,Nordgren H,Holmberg L,Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 17382.
  • 7
    Dumont P,Leu JI,Della Pietra AC,III,George DL,Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 35765.
  • 8
    Sullivan A,Syed N,Gasco M,Bergamaschi D,Trigiante G,Attard M,Hiller L,Farrell PJ,Smith P,Lu X,Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 332837.
  • 9
    Pim D,Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004; 108: 1969.
  • 10
    Xu Y,Yao L,Ouyang T,Li J,Wang T,Fan Z,Lin B,Lu Y,Xie Y. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005; 11: 732833.
  • 11
    Tommiska J,Eerola H,Heinonen M,Salonen L,Kaare M,Tallila J,Ristimaki A,von Smitten K,Aittomaki K,Heikkila P,Blomqvist C,Nevanlinna H. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005; 11: 5098103.
  • 12
    Tomizawa Y,Kohno T,Fujita T,Kiyama M,Saito R,Noguchi M,Matsuno Y,Hirohashi S,Yamaguchi N,Nakajima T,Yokota J. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 1999; 18: 100714.
  • 13
    Visscher DW,Sarkar FH,Shimoyama RK,Crissman JD. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol 1996; 5: 18793.
  • 14
    Li H,Yao L,Ouyang T,Li J,Wang T,Fan Z,Fan T,Dong B,Lin B,Li J,Xie Y. Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis 2007; 28: 3727.
  • 15
    Zhou Y,Li N,Zhuang W,Liu GJ,Wu TX,Yao X,Du L,Wei ML,Wu XT. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007; 121: 14816.
  • 16
    Langerod A,Bukholm IR,Bregard A,Lonning PE,Andersen TI,Rognum TO,Meling GI,Lothe RA,Borresen-Dale AL. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002; 11: 16848.
  • 17
    Hollstein M,Sidransky D,Vogelstein B,Harris CC. p53 mutations in human cancers. Science 1991; 253: 4953.
  • 18
    Caleffi M,Teague MW,Jensen RA,Vnencak-Jones CL,Dupont WD,Parl FF. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 1994; 73: 214756.
  • 19
    Storey A,Thomas M,Kalita A,Harwood C,Gardiol D,Mantovani F,Breuer J,Leigh IM,Matlashewski G,Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 22934.
  • 20
    Rosenthal AN,Ryan A,Al-Jehani RM,Storey A,Harwood CA,Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998; 352: 8712.
  • 21
    Noma C,Miyoshi Y,Taguchi T,Tamaki Y,Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 2004; 210: 197203.
  • 22
    Liu G,Miller DP,Zhou W,Thurston SW,Fan R,Xu LL,Lynch TJ,Wain JC,Su L,Christiani DC. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 2001; 61: 871822.
  • 23
    Perez-Perez GI,Bosques-Padilla FJ,Crosatti ML,Tijerina-Menchaca R,Garza-Gonzalez E. Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol 2005; 40: 5660.
  • 24
    Zhang ZW,Laurence NJ,Hollowood A,Newcomb P,Moorghen M,Gupta J,Feakins R,Farthing MJ,Alderson D,Holly J. Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma. Clin Cancer Res 2004; 10: 1315.
  • 25
    Bonafe M,Ceccarelli C,Farabegoli F,Santini D,Taffurelli M,Barbi C,Marzi E,Trapassi C,Storci G,Olivieri F,Franceschi C. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003; 9: 48604.
  • 26
    Wang YC,Chen CY,Chen SK,Chang YY,Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999; 5: 12934.
  • 27
    Wegman P,Stal O,Askmalm MS,Nordenskjold B,Rutqvist LE,Wingren S. p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet Genomics 2006; 16: 34751.
  • 28
    Hu Y,McDermott MP,Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 2005; 11: 25029.
  • 29
    Galic V,Willner J,Wollan M,Garg R,Garcia R,Goff BA,Gray HJ,Swisher EM. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 2007; 46: 23947.
  • 30
    Di Como CJ,Gaiddon C,Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19: 143849.
  • 31
    Gaiddon C,Lokshin M,Ahn J,Zhang T,Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21: 187487.
  • 32
    Marin MC,Jost CA,Brooks LA,Irwin MS,O'Nions J,Tidy JA,James N,McGregor JM,Harwood CA,Yulug IG,Vousden KH,Allday MJ, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25: 4754.
  • 33
    Bergamaschi D,Gasco M,Hiller L,Sullivan A,Syed N,Trigiante G,Yulug I,Merlano M,Numico G,Comino A,Attard M,Reelfs O, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387402.
  • 34
    Toyama T,Zhang Z,Nishio M,Hamaguchi M,Kondo N,Iwase H,Iwata H,Takahashi S,Yamashita H,Fujii Y. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007; 9: R34.